Device type · DHX
System, Test, Carcinoembryonic Antigen
Last checked: Nov 20, 2026Source: openFDAMethods & limitations
Product code
DHX
Immunology
Device class
Class II
FDA decisions since 2015
3
510(k), De Novo and PMA
Adverse event reports
19
Received Nov 1, 2025 to Nov 20, 2026
How FDA classifies it
- Device type
- System, Test, Carcinoembryonic Antigen
- Product code
- DHX
- Device class
- Class II
- Review panel
- Immunology
- Regulation
- 21 CFR 866.6010
- Specialty
- Laboratory Medicine & Pathology
- FDA record
- Classification database entry for DHX
Latest FDA decisions
- Access CEA510(k)
K223921 · Decided Sep 22, 2023 · 267 days after receipt
Device type: System, Test, Carcinoembryonic Antigen (DHX) · Laboratory Medicine & Pathology
K231517 · Decided Aug 23, 2023 · 90 days after receipt
Device type: System, Test, Carcinoembryonic Antigen (DHX) · Laboratory Medicine & Pathology
- ADVIA Centaur CEA Assay510(k)
Siemens Healthcare Disgnostics, Inc.
K200215 · Decided Apr 13, 2020 · 76 days after receipt
Device type: System, Test, Carcinoembryonic Antigen (DHX) · Laboratory Medicine & Pathology
Reports received
19
Received Nov 1, 2025 to Nov 20, 2026
Malfunction reports
19
100% of reports
Injury reports
0
0.0% of reports
Death reports
0
0.0% of reports
Adverse event reports received per month
By the date FDA received each report, stacked by event type. The newest month is incomplete.
- Malfunction
- Injury
- Death
- Other
View as table
| Month | Malfunction | Injury | Death | Other |
|---|---|---|---|---|
| Dec 23 | 0 | 0 | 0 | 0 |
| Jan 24 | 0 | 0 | 0 | 0 |
| Feb 24 | 1 | 0 | 0 | 0 |
| Mar 24 | 0 | 0 | 0 | 0 |
| Apr 24 | 0 | 0 | 0 | 0 |
| May 24 | 2 | 0 | 0 | 0 |
| Jun 24 | 3 | 0 | 0 | 0 |
| Jul 24 | 1 | 0 | 0 | 0 |
| Aug 24 | 2 | 0 | 0 | 0 |
| Sep 24 | 1 | 0 | 0 | 0 |
| Oct 24 | 2 | 0 | 0 | 0 |
| Nov 24 | 1 | 0 | 0 | 0 |
| Dec 24 | 2 | 0 | 0 | 0 |
| Jan 25 | 2 | 0 | 0 | 0 |
| Feb 25 | 1 | 0 | 0 | 0 |
| Mar 25 | 1 | 0 | 0 | 0 |
| Apr 25 | 1 | 0 | 0 | 0 |
| May 25 | 5 | 0 | 0 | 0 |
| Jun 25 | 2 | 0 | 0 | 0 |
| Jul 25 | 0 | 0 | 0 | 0 |
| Aug 25 | 0 | 0 | 0 | 0 |
| Sep 25 | 1 | 0 | 0 | 0 |
| Oct 25 | 2 | 0 | 0 | 0 |
| Nov 25 | 1 | 0 | 0 | 0 |
| Dec 25 | 3 | 0 | 0 | 0 |
| Jan 26 | 4 | 0 | 0 | 0 |
| Feb 26 | 0 | 0 | 0 | 0 |
| Mar 26 | 0 | 0 | 0 | 0 |
| Apr 26 | 1 | 0 | 0 | 0 |
| May 26 | 3 | 0 | 0 | 0 |
| Jun 26 | 1 | 0 | 0 | 0 |
| Jul 26 | 2 | 0 | 0 | 0 |
| Aug 26 | 1 | 0 | 0 | 0 |
| Sep 26 | 0 | 0 | 0 | 0 |
| Oct 26 | 3 | 0 | 0 | 0 |
| Nov 26 | 0 | 0 | 0 | 0 |
Manufacturers named most often
Last 12 months. Bigger sellers get more reports. This is not a ranking of safety.
1 more in this ranking with a free account
Device problems as coded
Last 12 months. FDA's terms. A report can carry several.
- High Test Results10
- Low Test Results9
- Non Reproducible Results9
2 more in this ranking with a free account
Patient problems as coded
Last 12 months. FDA's terms. A report can carry several.
- No Clinical Signs, Symptoms or Conditions19
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-2066-2018 · Started Mar 5, 2018
Reason given: Asfotase Alfa (Strensiq) interferes with certain Tosoh assays which potentially causes falsely increased or falsely decreased immunoassay test results, depending upon the assay.
Cause as FDA categorized it: Device Design
- IMMULITE /IMMULITE 1000 CEATerminated
Siemens Healthcare Diagnostics, Inc.
Z-1678-2018 · Started Jan 2, 2018 · Posted by FDA May 4, 2018
Reason given: Concentrations for the level of biotin that does not interfere is not currently listed in the instruction for use for the Dimension Vista CTNI, Dimension Vista MMB, Dimension Sirolimus, ADVIA Centaur FOL, ADVIA Centaur aHBcM and the following IMMULITE assays, 3gAllergy Specific IgE, anti-HBc, BR-MA (CA15-3), CEA,...
Cause as FDA categorized it: Error in labeling
- IMMULITE 2000/IMMULITE 2000 XPi CEATerminated
Siemens Healthcare Diagnostics, Inc.
Z-1679-2018 · Started Jan 2, 2018 · Posted by FDA May 4, 2018
Reason given: Concentrations for the level of biotin that does not interfere is not currently listed in the instruction for use for the Dimension Vista CTNI, Dimension Vista MMB, Dimension Sirolimus, ADVIA Centaur FOL, ADVIA Centaur aHBcM and the following IMMULITE assays, 3gAllergy Specific IgE, anti-HBc, BR-MA (CA15-3), CEA,...
Cause as FDA categorized it: Error in labeling
6 more recall records with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.